← 483 OBSERVATION EXPLORER

FDA 483 OBSERVATION · #319 OF 1,000 MOST-CITED

Infection with communicable disease agents

FDA cited this observation 66 times across 54 firms in recent inspections. Below: how it breaks down by program area and fiscal year, and real examples of how FDA worded it on Form FDA 483.

BY PROGRAM AREA
Human Tissue for Transplantation66
BY FISCAL YEAR
FY20256
FY20247
FY20232
FY202213
FY20216
FY202011
FY201910
FY201810
FY20171

What this observation is associated with

Firms cited for this observation also appear in FDA compliance actions — warning letters, injunctions, or seizures — at 3.1× the rate of the average FDA-cited firm (25.9% vs 8.3%), across 54 FEI-matched firms.

This is an association, not causation, and reflects co-occurrence in FDA's records — not a claim that the observation caused or preceded the action.

CHECKING ACCESS

Checking your Professional access…

How FDA worded it — real examples

Donors were not tested for evidence of infection with relevant communicable disease agents.

Arizona Reproductive Medicine Specialists · Phoenix, Arizona · Human Tissue for Transplantation · 2025-06-30

Donors were not tested for evidence of infection with relevant communicable disease agents.

Louisville Reproductive Center · Louisville, Kentucky · Human Tissue for Transplantation · 2025-04-28

Donors were not tested for evidence of infection with relevant communicable disease agents.

BioXtek LLC · Pompano Beach, Florida · Human Tissue for Transplantation · 2025-02-26

Donors were not tested for evidence of infection with relevant communicable disease agents.

Billings Clinic Fertility Specialists · Bozeman, Montana · Human Tissue for Transplantation · 2025-02-26

Donors were not tested for evidence of infection with relevant communicable disease agents.

InVia Fertility Specialists, PLLC · Hoffman Estates, Illinois · Human Tissue for Transplantation · 2025-02-05

Donors were not tested for evidence of infection with relevant communicable disease agents.

University Fertility Laboratory, Inc. · Torrance, California · Human Tissue for Transplantation · 2025-01-17

Examples are a representative sample of FDA's published inspection observations. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →